Multidisciplinary Treatment With Hepatic Arterial Infusion Chemotherapy, Radiotherapy, and Immunotherapy for Advanced Hepatocellular Carcinoma With Major Vascular Invasion: Prospective Registry Protocol
JMIR Research Protocols · 2026
DOI: 10.2196/82992 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JMIR Research Protocols, 2026. Verfasst von Yoshiko Doi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Systemic therapy, including immune checkpoint inhibitors, has improved survival in advanced hepatocellular carcinoma (HCC); however, its efficacy remains limited in patients with macroscopic vascular invasion (MVI), a subgroup with an extremely poor prognosis. Although combining immunotherapy with local treatments such as hepatic arterial infusion chemotherapy (HAIC) and radiation therapy (RT) is considered a promising approach, robust supportive evidence from routine clinical practice is lacking.
Objective
This study aims to evaluate the safety and therapeutic effectiveness of a multidisciplinary treatment strategy involving RT after HAIC, followed by immunotherapy, in patients with MVI-positive HCC, using real-world clinical data from Japan.
Methods
This is a prospective, multicenter registry study conducted at 3 hospitals in Hiroshima Prefecture, Japan. Eligible patients will have unresectable MVI-positive HCC confirmed by dynamic computed tomography. The treatment protocol follows a standardized sequence: 1 session of HAIC (cisplatin), RT targeting the MVI site (25 Gy in 5 fractions), and subsequent systemic immunotherapy. The primary end point is safety, which will be evaluated using the Common Terminology Criteria for Adverse Events (version 5.0). The secondary end points include progression-free survival at 12 and 24 weeks, tumor response, median progression-free survival, overall survival, and objective response rate at 12 and 24 weeks, assessed according to the Response Evaluation Criteria in Solid Tumors criteria. Data will be collected prospectively and analyzed according to the intention-to-treat principle.
Results
Patient enrollment began in March 2025, and data collection and analysis are ongoing as participants continue to be followed.
Conclusions
This prospective registry study will generate real-world evidence on the safety and effectiveness of a multidisciplinary strategy combining HAIC, RT, and immunotherapy in patients with MVI-positive HCC. Given that all components are covered under Japan’s national health insurance, this approach could be readily implemented in clinical practice and may inform future treatment guidelines for MVI-positive HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
- Department of Gastroenterology and Hepatology, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan, +81 82 254 1818.
- Department of Medical Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
- Department of Diagnostic Radiology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
- Department of Gastroenterological Surgery, Hiroshima Prefectural Hospital, Hiroshima, Japan.
- Department of Radiation Oncology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan.
ORCID-Profile: Yoshiko Doi, Hiroshi Aikata, Yumi Kosaka, Takashi Nakahara, Michiyo Kodama, Masashi Hieda, Masakazu Hashimoto, Hideki Nakahara, Ippei Takahashi, Hideaki Kakizawa, Nami Mori, Keiji Tsuji, Nobuki Imano, Yuji Murakami, Saki Sueda, Tomokazu Kawaoka, Masataka Tsuge, Shiro Oka
Zitieren
APA
Doi, Y., Aikata, H., Kosaka, Y., Nakahara, T., Kodama, M., Hieda, M., Hashimoto, M., Nakahara, H., Takahashi, I., Kakizawa, H., Mori, N., Tsuji, K., Imano, N., Murakami, Y., Sueda, S., Kawaoka, T., Tsuge, M., & Oka, S. (2026). Multidisciplinary Treatment With Hepatic Arterial Infusion Chemotherapy, Radiotherapy, and Immunotherapy for Advanced Hepatocellular Carcinoma With Major Vascular Invasion: Prospective Registry Protocol. JMIR Research Protocols. https://doi.org/10.2196/82992
Vancouver
Doi Y, Aikata H, Kosaka Y, Nakahara T, Kodama M, Hieda M, et al. Multidisciplinary Treatment With Hepatic Arterial Infusion Chemotherapy, Radiotherapy, and Immunotherapy for Advanced Hepatocellular Carcinoma With Major Vascular Invasion: Prospective Registry Protocol. JMIR Research Protocols. 2026. doi:10.2196/82992
BibTeX
@article{Doi2026,
author = {Doi, Yoshiko and Aikata, Hiroshi and Kosaka, Yumi and Nakahara, Takashi and Kodama, Michiyo and Hieda, Masashi and Hashimoto, Masakazu and Nakahara, Hideki and Takahashi, Ippei and Kakizawa, Hideaki and Mori, Nami and Tsuji, Keiji and Imano, Nobuki and Murakami, Yuji and Sueda, Saki and Kawaoka, Tomokazu and Tsuge, Masataka and Oka, Shiro},
title = {Multidisciplinary Treatment With Hepatic Arterial Infusion Chemotherapy, Radiotherapy, and Immunotherapy for Advanced Hepatocellular Carcinoma With Major Vascular Invasion: Prospective Registry Protocol},
journal = {JMIR Research Protocols},
year = {2026},
doi = {10.2196/82992}
}
EUVIMED